Showing results (11-20 of 715) with videos related to
Sort By:
Pageof 72
Diagnostic and Interventional Imaging|May 14, 2024
The cutting edge: Promising oncology radiotracers in clinical developmentJorge D Oldan, Martin G Pomper, Rudolf A Werner, et al.Bioconjugate Chemistry|January 14, 2014
Heterobivalent agents targeting PSMA and integrin-αvβ3Hassan M Shallal, Il Minn, Sangeeta R Banerjee, et al.Radiologic Clinics of North America|April 30, 2021
Cellular and Molecular Imaging with SPECT and PET in Brain TumorsMohammad S Sadaghiani, Sara Sheikhbahaei, Steven P Rowe, et al.Seminars in Nuclear Medicine|January 21, 2022
SPECT and PET Radiotracers in Renal ImagingRudolf A Werner, Martin G Pomper, Andreas K Buck, et al.Journal of Labelled Compounds & Radiopharmaceuticals|February 12, 2021
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111 In]In-XYIMSR-01 for phase I regulatory approvalRavindra A De Silva, Michael A Gorin, Ronnie C Mease, et al.Science Advances|July 9, 2019
Imaging CAR T cell therapy with PSMA-targeted positron emission tomographyIl Minn, David J Huss, Hye-Hyun Ahn, et al.Journal of Biophotonics|April 14, 2018
Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivoHaichong K Zhang, Ying Chen, Jeeun Kang, et al.Nuclear Medicine and Biology|May 27, 2018
Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitorsGanesan Vaidyanathan, Choong Mo Kang, Darryl McDougald, et al.Pharmaceutics|February 26, 2022
A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target EffectsBei Cheng, Hye-Hyun Ahn, Hwanhee Nam, et al.Abdominal Radiology (New York)|May 18, 2020
Recent updates and developments in PET imaging of prostate cancerSteven P Rowe, Geoffrey B Johnson, Martin G Pomper, et al.Pageof 72